Patients with smouldering multiple myeloma (SMM) or indolent multiple myeloma (IMM) after targeted treatment on the IL-1/IL-6 axis using Anakinra (an IL-1 receptor antagonist; IL-1Ra) showed improvement in PFS (progression-free survival) and overall survival (OS) parameters [14]. Here, IL1B is linked to plasma cell myeloma.